RNA aptamers and use thereof for treating cancer
Provided herein are RNA aptamers targeting CD5L. Further provided herein are methods of use thereof for the treatment of a disease or disorder, such as cancer.
1 . An RNA aptamer that specifically binds to CD5 antigen-like precursor (CD5L), wherein the aptamer comprises SEQ ID NO:5 or SEQ ID NO:6 and has a KD value of about 20 nM or less.
2 . The RNA aptamer of claim 1 , further comprising at least one modified nucleotide.
3 . The RNA aptamer of claim 1 , where the aptamer comprises at least one 2′-modified nucleotide.
4 . The RNA aptamer of claim 3 , wherein at least one nucleotide is chemically modified with 2′-fluoropyrimidine.
5 . The RNA aptamer of claim 3 , wherein all of the pyrimidines are chemically modified with 2′-fluoro pyrimidine.
6 . The RNA aptamer of claim 1 , where the aptamer is covalently linked to a carrier selected from the group consisting of a soluble polymer, a biodegradable polymer, polyethylene glycol, and cholesterol.
7 . The RNA aptamer of claim 1 , wherein the aptamer is 40-100 nucleotides in length.
8 . The RNA aptamer of claim 1 , wherein the aptamer comprises SEQ ID NO:5.
9 . The RNA aptamer of claim 1 , wherein the aptamer comprises SEQ ID NO: 6.
10 . The RNA aptamer of claim 1 , wherein the aptamer is single-stranded.
11 . The RNA aptamer of claim 1 , wherein the aptamer folds into at least one hairpin-like structure.
12 . The RNA aptamer of claim 1 , wherein the aptamer further comprises a detectable label.
13 . A composition comprising a therapeutically effective amount of an RNA aptamer of claim 1 , and a pharmaceutically acceptable diluent or vehicle.
14 . A method of treating a cancer in a patient comprising administering an effective amount of an RNA aptamer of claim 1 to the patient.
15 . The method of claim 14 , wherein the cancer is ovarian cancer.
16 . The method of claim 14 , wherein the patient's serum has been determined to have an elevated level of CD5L.